8-K: Y-mAbs Therapeutics Reaches $19.65 Million Settlement in Securities Class Action Lawsuit

Y-mAbs Therapeutics has agreed to a $19.65 million settlement to resolve a securities class action lawsuit, with the majority of the payment expected to be covered by insurance.

Summary

• Y-mAbs Therapeutics has reached a settlement agreement in a securities class action lawsuit.
• The lawsuit, filed on January 18, 2023, alleged violations of the Securities Exchange Act of 1934.
• The proposed class consisted of investors who purchased Y-mAbs stock between October 6, 2020, and October 28, 2022.
• The settlement amount is $19.65 million.
• Approximately 80% of the settlement is expected to be paid by the company's insurance carriers.
• The company anticipates that its portion of the settlement will not significantly impact its cash runway.
• The settlement does not constitute an admission of fault or wrongdoing by the company or any individual defendants.
• The settlement is subject to preliminary and final approval by the United States District Court for the Southern District of New York.

Sentiment

Score: 6

Explanation: The settlement is a positive step towards resolving a legal issue, but the company still has to pay a portion of the settlement and there are risks associated with the court approval process. The insurance coverage is a positive factor.

Positives

• The settlement is expected to resolve the securities class action lawsuit.
• The majority of the settlement cost is expected to be covered by insurance.
• The company anticipates minimal impact on its cash runway from the settlement.

Negatives

• The company is required to pay a portion of the $19.65 million settlement.
• The settlement is subject to court approval and may not be finalized.
• There is a risk that individual claimants may opt out of the class and pursue separate claims.

Risks

• The settlement may not be approved by the court.
• The company's insurance carriers may not fully cover their expected portion of the settlement.
• The company may face additional costs or delays related to the settlement.
• Individual claimants may opt out of the class and pursue separate legal action.
• The company may face future litigation or disagreements.

Future Outlook

The company is seeking court approval for the settlement and expects the settlement to resolve the securities class action lawsuit. The company has cautioned that there are risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.

Management Comments

• The proposed settlement does not constitute an admission of fault or wrongdoing by the Company or any of the individual defendants.

Industry Context

Securities class action lawsuits are not uncommon for publicly traded companies, particularly in the biotechnology sector. This settlement is a step towards resolving a legal issue and allowing the company to focus on its core business operations.

Comparison to Industry Standards

• Settlements in securities class action lawsuits vary widely depending on the size of the company, the nature of the allegations, and the stage of the litigation.
• A $19.65 million settlement is within the range of settlements seen in similar cases, but the impact on Y-mAbs is mitigated by the insurance coverage.
• Other biotech companies such as Amgen and Biogen have faced similar lawsuits, with settlement amounts ranging from a few million to hundreds of millions of dollars.
• The fact that 80% of the settlement is expected to be covered by insurance is a positive outcome for Y-mAbs compared to companies that have had to bear the full cost of settlements.

Legal Proceedings

• The company was involved in a securities class action lawsuit in the United States District Court for the Southern District of New York.
• The lawsuit alleged violations of the Securities Exchange Act of 1934.
• The company has reached a settlement agreement to resolve the lawsuit.

Stakeholder Impact

• Shareholders will be impacted by the settlement, but the financial impact is expected to be mitigated by insurance coverage.
• The settlement is expected to resolve a legal uncertainty, which is a positive for stakeholders.
• The company's cash runway is not expected to be significantly impacted by the settlement.

Next Steps

• The company will seek preliminary and final approval of the settlement from the United States District Court for the Southern District of New York.
• The company will work with its insurance carriers to ensure timely payment of their portion of the settlement.

Key Dates

Keywords

securities litigation, class action, settlement, insurance, legal, Y-mAbs Therapeutics, lawsuit